ID   EPHA1_HUMAN             Reviewed;         976 AA.
AC   P21709; A1L3V3; B5A966; B5A967; Q15405;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   12-OCT-2022, entry version 226.
DE   RecName: Full=Ephrin type-A receptor 1;
DE            Short=hEpha1;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH tyrosine kinase;
DE   AltName: Full=EPH tyrosine kinase 1;
DE   AltName: Full=Erythropoietin-producing hepatoma receptor;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH;
DE   Flags: Precursor;
GN   Name=EPHA1; Synonyms=EPH, EPHT, EPHT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-160 AND VAL-900.
RX   PubMed=2825356; DOI=10.1126/science.2825356;
RA   Hirai H., Maru Y., Hagiwara K., Nishida J., Takaku F.;
RT   "A novel putative tyrosine kinase receptor encoded by the eph gene.";
RL   Science 238:1717-1720(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-160 AND VAL-900.
RX   PubMed=10369740; DOI=10.1006/mcpr.1999.0228;
RA   Owshalimpur D., Kelley M.J.;
RT   "Genomic structure of the EPHA1 receptor tyrosine kinase gene.";
RL   Mol. Cell. Probes 13:169-173(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ALA-160 AND
RP   VAL-900.
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ALA-160 AND
RP   VAL-900.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ALA-160
RP   AND VAL-900.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 286-976 (ISOFORM 1), AND VARIANT VAL-900.
RC   TISSUE=Placenta;
RA   Tuzi N.L.;
RT   "An EGFR/eph chimeric receptor possesses ligand stimulated tyrosine kinase
RT   activity and promotes cell growth.";
RL   Submitted (MAY-1994) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [10]
RP   FUNCTION IN MIGRATION OF T-LYMPHOCYTES, AND INTERACTION WITH LCK;
RP   PTK2B/PYK2 AND PI3-KINASE.
RX   PubMed=17634955; DOI=10.1002/eji.200737111;
RA   Hjorthaug H.S., Aasheim H.C.;
RT   "Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.";
RL   Eur. J. Immunol. 37:2326-2336(2007).
RN   [11]
RP   FUNCTION IN CELL SPREADING, FUNCTION IN CELL MIGRATION,
RP   AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH PTK2/FAK1
RP   AND ILK.
RX   PubMed=19118217; DOI=10.1242/jcs.036467;
RA   Yamazaki T., Masuda J., Omori T., Usui R., Akiyama H., Maru Y.;
RT   "EphA1 interacts with integrin-linked kinase and regulates cell morphology
RT   and motility.";
RL   J. Cell Sci. 122:243-255(2009).
RN   [12]
RP   FUNCTION IN ANGIOGENESIS, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=20043122;
RA   Chen G., Wang Y., Zhou M., Shi H., Yu Z., Zhu Y., Yu F.;
RT   "EphA1 receptor silencing by small interfering RNA has antiangiogenic and
RT   antitumor efficacy in hepatocellular carcinoma.";
RL   Oncol. Rep. 23:563-570(2010).
RN   [13]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-906 AND SER-910, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   STRUCTURE BY NMR OF 536-573, AND HOMODIMERIZATION.
RX   PubMed=18728013; DOI=10.1074/jbc.m803089200;
RA   Bocharov E.V., Mayzel M.L., Volynsky P.E., Goncharuk M.V., Ermolyuk Y.S.,
RA   Schulga A.A., Artemenko E.O., Efremov R.G., Arseniev A.S.;
RT   "Spatial structure and pH-dependent conformational diversity of dimeric
RT   transmembrane domain of the receptor tyrosine kinase EphA1.";
RL   J. Biol. Chem. 283:29385-29395(2008).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 911-974.
RG   Structural genomics consortium (SGC);
RT   "Sam domain of human ephrin type-a receptor 1 (epha1).";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-160; CYS-351; GLN-492; GLN-575;
RP   THR-585; LEU-697; LYS-703; ARG-807 AND VAL-900.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-900, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane-
CC       bound ephrin-A family ligands residing on adjacent cells, leading to
CC       contact-dependent bidirectional signaling into neighboring cells. The
CC       signaling pathway downstream of the receptor is referred to as forward
CC       signaling while the signaling pathway downstream of the ephrin ligand
CC       is referred to as reverse signaling. Binds with a low affinity EFNA3
CC       and EFNA4 and with a high affinity to EFNA1 which most probably
CC       constitutes its cognate/functional ligand. Upon activation by EFNA1
CC       induces cell attachment to the extracellular matrix inhibiting cell
CC       spreading and motility through regulation of ILK and downstream RHOA
CC       and RAC. Also plays a role in angiogenesis and regulates cell
CC       proliferation. May play a role in apoptosis.
CC       {ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:19118217,
CC       ECO:0000269|PubMed:20043122}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Homodimer. Forms a signaling complex with LCK; PTK2B/PYK2 and
CC       PI3-kinase upon activation by EFNA1; regulates T-lymphocytes migration.
CC       Interacts (via SAM domain) with ILK (via ANK repeats); stimulated by
CC       EFNA1 but independent of the kinase activity of EPHA1. Interacts
CC       (kinase activity-dependent) with PTK2/FAK1.
CC       {ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:19118217}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19118217};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:19118217}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P21709-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21709-2; Sequence=VSP_056010, VSP_056013;
CC       Name=3;
CC         IsoId=P21709-3; Sequence=VSP_056011, VSP_056012;
CC   -!- TISSUE SPECIFICITY: Overexpressed in several carcinomas.
CC   -!- PTM: Phosphorylated. Autophosphorylation is stimulated by its ligand
CC       EFNA1.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36747.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA1ID40461ch7q35.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M18391; AAA36747.1; ALT_FRAME; mRNA.
DR   EMBL; AF101171; AAD43440.1; -; Genomic_DNA.
DR   EMBL; AF101165; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; AF101166; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; AF101167; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; AF101168; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; AF101169; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; AF101170; AAD43440.1; JOINED; Genomic_DNA.
DR   EMBL; EU826604; ACF47640.1; -; mRNA.
DR   EMBL; EU826605; ACF47641.1; -; mRNA.
DR   EMBL; AC092214; AAS07458.1; -; Genomic_DNA.
DR   EMBL; CH236959; EAL23789.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51846.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51847.1; -; Genomic_DNA.
DR   EMBL; BC130291; AAI30292.1; -; mRNA.
DR   EMBL; Z27409; CAA81796.1; -; mRNA.
DR   CCDS; CCDS5884.1; -. [P21709-1]
DR   PIR; A34076; A34076.
DR   RefSeq; NP_005223.4; NM_005232.4. [P21709-1]
DR   PDB; 2K1K; NMR; -; A/B=536-573.
DR   PDB; 2K1L; NMR; -; A/B=536-573.
DR   PDB; 3HIL; X-ray; 2.00 A; A/B=911-974.
DR   PDB; 3KKA; X-ray; 2.40 A; A/B=911-974.
DR   PDBsum; 2K1K; -.
DR   PDBsum; 2K1L; -.
DR   PDBsum; 3HIL; -.
DR   PDBsum; 3KKA; -.
DR   AlphaFoldDB; P21709; -.
DR   BMRB; P21709; -.
DR   SMR; P21709; -.
DR   BioGRID; 108355; 128.
DR   CORUM; P21709; -.
DR   DIP; DIP-34886N; -.
DR   IntAct; P21709; 236.
DR   MINT; P21709; -.
DR   STRING; 9606.ENSP00000275815; -.
DR   BindingDB; P21709; -.
DR   ChEMBL; CHEMBL5810; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P21709; -.
DR   GuidetoPHARMACOLOGY; 1821; -.
DR   GlyGen; P21709; 1 site.
DR   iPTMnet; P21709; -.
DR   PhosphoSitePlus; P21709; -.
DR   BioMuta; EPHA1; -.
DR   DMDM; 317373566; -.
DR   CPTAC; CPTAC-2782; -.
DR   EPD; P21709; -.
DR   jPOST; P21709; -.
DR   MassIVE; P21709; -.
DR   MaxQB; P21709; -.
DR   PaxDb; P21709; -.
DR   PeptideAtlas; P21709; -.
DR   PRIDE; P21709; -.
DR   ProteomicsDB; 53891; -. [P21709-1]
DR   Antibodypedia; 32658; 627 antibodies from 38 providers.
DR   DNASU; 2041; -.
DR   Ensembl; ENST00000275815.4; ENSP00000275815.3; ENSG00000146904.9. [P21709-1]
DR   Ensembl; ENST00000645847.2; ENSP00000494931.1; ENSG00000284816.2. [P21709-1]
DR   GeneID; 2041; -.
DR   KEGG; hsa:2041; -.
DR   MANE-Select; ENST00000275815.4; ENSP00000275815.3; NM_005232.5; NP_005223.4.
DR   UCSC; uc003wcz.3; human. [P21709-1]
DR   CTD; 2041; -.
DR   DisGeNET; 2041; -.
DR   GeneCards; EPHA1; -.
DR   HGNC; HGNC:3385; EPHA1.
DR   HPA; ENSG00000146904; Group enriched (esophagus, parathyroid gland).
DR   MIM; 179610; gene.
DR   neXtProt; NX_P21709; -.
DR   OpenTargets; ENSG00000146904; -.
DR   PharmGKB; PA27817; -.
DR   VEuPathDB; HostDB:ENSG00000146904; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000160920; -.
DR   HOGENOM; CLU_000288_141_0_1; -.
DR   InParanoid; P21709; -.
DR   OMA; YQRCPEA; -.
DR   OrthoDB; 933071at2759; -.
DR   PhylomeDB; P21709; -.
DR   TreeFam; TF315363; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P21709; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-2892247; POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P21709; -.
DR   SIGNOR; P21709; -.
DR   BioGRID-ORCS; 2041; 8 hits in 1107 CRISPR screens.
DR   ChiTaRS; EPHA1; human.
DR   EvolutionaryTrace; P21709; -.
DR   GeneWiki; EPH_receptor_A1; -.
DR   GenomeRNAi; 2041; -.
DR   Pharos; P21709; Tchem.
DR   PRO; PR:P21709; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P21709; protein.
DR   Bgee; ENSG00000146904; Expressed in lower esophagus mucosa and 91 other tissues.
DR   Genevisible; P21709; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0001968; F:fibronectin binding; IDA:ARUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10479; EphR_LBD_A1; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034251; EphA1_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell adhesion; Cell membrane; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..976
FT                   /note="Ephrin type-A receptor 1"
FT                   /id="PRO_0000016798"
FT   TOPO_DOM        26..547
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        548..568
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        569..976
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          27..209
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          332..445
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          447..538
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          624..884
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          913..976
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           974..976
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        749
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         630..638
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         656
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         599
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         605
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         781
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         906
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         910
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         930
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        414
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         446..490
FT                   /note="ESLSGLSLRLVKKEPRQLELTWAGSRPRSPGANLTYELHVLNQDE -> DPT
FT                   LSLWTPRVTVRPVSETGEERTEATRADLGGVPAPKPWGEPDL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056010"
FT   VAR_SEQ         446..474
FT                   /note="ESLSGLSLRLVKKEPRQLELTWAGSRPRS -> GERLRGAGTGTWWRQKGLR
FT                   PQNKLMGRKP (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056011"
FT   VAR_SEQ         475..976
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056012"
FT   VAR_SEQ         491..976
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056013"
FT   VARIANT         160
FT                   /note="V -> A (in dbSNP:rs4725617)"
FT                   /evidence="ECO:0000269|PubMed:10369740,
FT                   ECO:0000269|PubMed:12690205, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:2825356,
FT                   ECO:0000269|Ref.6"
FT                   /id="VAR_028265"
FT   VARIANT         351
FT                   /note="R -> C (in dbSNP:rs56006153)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042115"
FT   VARIANT         492
FT                   /note="R -> Q (in dbSNP:rs11768549)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_028266"
FT   VARIANT         575
FT                   /note="R -> Q (in dbSNP:rs35719334)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042116"
FT   VARIANT         585
FT                   /note="A -> T (in dbSNP:rs34178823)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042117"
FT   VARIANT         697
FT                   /note="P -> L (in dbSNP:rs34372369)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042118"
FT   VARIANT         703
FT                   /note="E -> K (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042119"
FT   VARIANT         807
FT                   /note="S -> R (in dbSNP:rs56244405)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042120"
FT   VARIANT         900
FT                   /note="M -> V (in dbSNP:rs6967117)"
FT                   /evidence="ECO:0000269|PubMed:10369740,
FT                   ECO:0000269|PubMed:12690205, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:2825356,
FT                   ECO:0000269|Ref.6, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19369195"
FT                   /id="VAR_028267"
FT   CONFLICT        398
FT                   /note="G -> A (in Ref. 2; AAD43440 and 8; CAA81796)"
FT                   /evidence="ECO:0000305"
FT   STRAND          538..540
FT                   /evidence="ECO:0007829|PDB:2K1K"
FT   HELIX           545..570
FT                   /evidence="ECO:0007829|PDB:2K1K"
FT   HELIX           918..924
FT                   /evidence="ECO:0007829|PDB:3HIL"
FT   HELIX           928..930
FT                   /evidence="ECO:0007829|PDB:3HIL"
FT   HELIX           931..936
FT                   /evidence="ECO:0007829|PDB:3HIL"
FT   HELIX           942..945
FT                   /evidence="ECO:0007829|PDB:3HIL"
FT   HELIX           950..955
FT                   /evidence="ECO:0007829|PDB:3HIL"
FT   HELIX           961..973
FT                   /evidence="ECO:0007829|PDB:3HIL"
SQ   SEQUENCE   976 AA;  108127 MW;  91EFCA69FFE17826 CRC64;
     MERRWPLGLG LVLLLCAPLP PGARAKEVTL MDTSKAQGEL GWLLDPPKDG WSEQQQILNG
     TPLYMYQDCP MQGRRDTDHW LRSNWIYRGE EASRVHVELQ FTVRDCKSFP GGAGPLGCKE
     TFNLLYMESD QDVGIQLRRP LFQKVTTVAA DQSFTIRDLV SGSVKLNVER CSLGRLTRRG
     LYLAFHNPGA CVALVSVRVF YQRCPETLNG LAQFPDTLPG PAGLVEVAGT CLPHARASPR
     PSGAPRMHCS PDGEWLVPVG RCHCEPGYEE GGSGEACVAC PSGSYRMDMD TPHCLTCPQQ
     STAESEGATI CTCESGHYRA PGEGPQVACT GPPSAPRNLS FSASGTQLSL RWEPPADTGG
     RQDVRYSVRC SQCQGTAQDG GPCQPCGVGV HFSPGARGLT TPAVHVNGLE PYANYTFNVE
     AQNGVSGLGS SGHASTSVSI SMGHAESLSG LSLRLVKKEP RQLELTWAGS RPRSPGANLT
     YELHVLNQDE ERYQMVLEPR VLLTELQPDT TYIVRVRMLT PLGPGPFSPD HEFRTSPPVS
     RGLTGGEIVA VIFGLLLGAA LLLGILVFRS RRAQRQRQQR QRDRATDVDR EDKLWLKPYV
     DLQAYEDPAQ GALDFTRELD PAWLMVDTVI GEGEFGEVYR GTLRLPSQDC KTVAIKTLKD
     TSPGGQWWNF LREATIMGQF SHPHILHLEG VVTKRKPIMI ITEFMENGAL DAFLREREDQ
     LVPGQLVAML QGIASGMNYL SNHNYVHRDL AARNILVNQN LCCKVSDFGL TRLLDDFDGT
     YETQGGKIPI RWTAPEAIAH RIFTTASDVW SFGIVMWEVL SFGDKPYGEM SNQEVMKSIE
     DGYRLPPPVD CPAPLYELMK NCWAYDRARR PHFQKLQAHL EQLLANPHSL RTIANFDPRM
     TLRLPSLSGS DGIPYRTVSE WLESIRMKRY ILHFHSAGLD TMECVLELTA EDLTQMGITL
     PGHQKRILCS IQGFKD
//
